Replimune Group’s (REPL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $17.00 target price on the stock. HC Wainwright also issued estimates for Replimune Group’s Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

A number of other brokerages have also recently weighed in on REPL. JPMorgan Chase & Co. boosted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Price Performance

REPL opened at $10.80 on Tuesday. The stock has a market cap of $738.94 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. Replimune Group has a 1 year low of $4.92 and a 1 year high of $12.97. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average price of $11.46 and a 200 day moving average price of $9.54.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Analysts forecast that Replimune Group will post -3.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its stake in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the period. Point72 DIFC Ltd bought a new position in shares of Replimune Group in the second quarter worth about $57,000. Arizona State Retirement System bought a new position in shares of Replimune Group in the second quarter worth about $108,000. Quest Partners LLC increased its stake in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares during the period. Finally, Erste Asset Management GmbH bought a new position in Replimune Group during the third quarter valued at about $133,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.